Equities research analysts expect that Depomed, Inc. (NASDAQ:DEPO) will announce $92.77 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Depomed’s earnings, with the highest sales estimate coming in at $93.59 million and the lowest estimate coming in at $91.95 million. Depomed posted sales of $123.91 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 25.1%. The company is scheduled to issue its next earnings results on Tuesday, February 20th.

On average, analysts expect that Depomed will report full-year sales of $92.77 million for the current year, with estimates ranging from $378.27 million to $402.90 million. For the next year, analysts anticipate that the business will post sales of $399.61 million per share, with estimates ranging from $374.96 million to $423.80 million. Zacks’ sales averages are an average based on a survey of research firms that cover Depomed.

Depomed (NASDAQ:DEPO) last announced its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.02. Depomed had a negative net margin of 27.73% and a negative return on equity of 51.07%. The firm had revenue of $95.40 million for the quarter, compared to analyst estimates of $99.11 million. During the same quarter last year, the business earned $0.28 earnings per share. Depomed’s revenue was down 13.7% compared to the same quarter last year.

A number of analysts recently issued reports on the stock. UBS AG raised their target price on shares of Depomed from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Friday, November 10th. ValuEngine lowered shares of Depomed from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 28th. Janney Montgomery Scott lowered shares of Depomed from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $18.00 to $8.00 in a research report on Tuesday, August 8th. Royal Bank Of Canada decreased their target price on shares of Depomed from $8.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 8th. Finally, BidaskClub lowered shares of Depomed from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $10.64.

A number of large investors have recently bought and sold shares of the business. GSA Capital Partners LLP raised its stake in Depomed by 133.5% during the third quarter. GSA Capital Partners LLP now owns 158,300 shares of the specialty pharmaceutical company’s stock worth $917,000 after purchasing an additional 90,500 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Depomed during the third quarter worth approximately $245,000. Engineers Gate Manager LP purchased a new position in Depomed during the third quarter worth approximately $812,000. OxFORD Asset Management LLP raised its stake in Depomed by 22.8% during the third quarter. OxFORD Asset Management LLP now owns 470,451 shares of the specialty pharmaceutical company’s stock worth $2,764,000 after purchasing an additional 87,332 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ raised its stake in Depomed by 5.7% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 295,800 shares of the specialty pharmaceutical company’s stock worth $1,713,000 after purchasing an additional 16,000 shares during the period. 90.52% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Depomed, Inc. (DEPO) Will Announce Quarterly Sales of $92.77 Million” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/21/brokerages-anticipate-depomed-inc-depo-will-announce-quarterly-sales-of-92-77-million.html.

Shares of Depomed (NASDAQ:DEPO) opened at $6.16 on Tuesday. Depomed has a 1 year low of $4.31 and a 1 year high of $21.38. The company has a quick ratio of 0.79, a current ratio of 0.83 and a debt-to-equity ratio of 2.90.

Depomed Company Profile

Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).

Get a free copy of the Zacks research report on Depomed (DEPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Depomed (NASDAQ:DEPO)

Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.